Clinical trials
Antibody clinical trials
Below are recruiting antibody clinical trials, each written for real people, not researchers. We’re tracking 540 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05841472RecruitingPhase 2
Camrelizumab plus chemo for advanced lung cancer without EGFR or ALK
This Phase 2 trial tests whether the immunotherapy drug camrelizumab, combined with pemetrexed and carboplatin, can work better as first treatment for advanced lung cancer that has no EGFR or ALK gene changes. You may be able to join if you have measurable disease, good enough organ function, and meet other safety rules for immune treatment.
AnamAges 19–80 - NCT06881537RecruitingPhase 2
Chemo and targeted therapy before surgery for recurrent colorectal cancer
This trial tests a combination of chemotherapy (CapeOX), a targeted drug (bevacizumab), and an immunotherapy (anti-PD1) given before surgery for colorectal cancer that has come back locally (in the same area). The goal is to shrink the tumor and improve surgical outcomes.
ShanghaiAges 18–75 - NCT06774365Recruiting
Heart imaging and blood tests for transplant rejection detection
This study uses advanced heart imaging and blood tests to detect a type of rejection that can happen after a heart transplant. It may help doctors diagnose antibody-mediated rejection earlier and more accurately.
Bari, BariAges 18 years+ - NCT05646550RecruitingPhase 1
Antibody CC-1 for men with returning prostate cancer
This Phase 1 study tests an antibody drug (CC-1) for men whose prostate cancer has come back, based on rising PSA blood tests. It looks at safety and how the treatment affects cancer activity, especially whether it can help control early biochemical recurrence.
TübingenAges 18 years+ - NCT06868836RecruitingPhase 2
Study of a new antibody combination for advanced lung cancer after targeted therapy
This trial tests a new drug (JS207) that targets both PD-1 and VEGF pathways, given alone or with other treatments, for people with advanced non-small cell lung cancer that has a specific gene change and has stopped responding to targeted therapy (TKI). The goal is to see if this combination can help shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18–75 - NCT06776861Recruiting
Radiation plus immunotherapy for advanced breast cancer
This study looks at combining radiation therapy with immunotherapy for advanced breast cancer that has spread or cannot be surgically removed. The goal is to see if adding radiation after treatment helps improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06824155RecruitingEarly Phase 1
Radioactive drug for HER2-positive advanced cancers
This trial tests a radioactive drug (lutetium-177) that targets the HER2 protein, which is found on some cancer cells. It's for people with advanced, HER2-positive or HER2-low solid tumors that haven't responded to other treatments.
Kingswood, New South WalesAges 18 years+ - NCT06625593RecruitingPhase 1
Study of BG-C137 for advanced solid tumors
This trial tests a new drug called BG-C137 for people with advanced solid tumors that have stopped responding to other treatments. The drug targets a protein called FGFR2b found on some cancer cells, aiming to deliver a therapy directly to the tumor.
Los Angeles, CaliforniaAges 18 years+ - NCT06617962Recruiting
Testing two new blood tests for MOGAD diagnosis
This study is testing two new blood tests to see if they can better diagnose MOGAD, an inflammatory condition that affects the brain and spinal cord. If you or your doctor suspects MOGAD, this trial may help confirm the diagnosis.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT05668403RecruitingPhase 1
Subcutaneous anti-CD20 antibody for primary membranous nephropathy
This Phase 1 study tests a skin-under-the-bone (subcutaneous) antibody medicine that targets CD20 on certain immune cells. It aims to see safety and how the drug may work in people with primary membranous nephropathy, a kidney disease that can cause high urine protein.
Zhengzhou, He'nanAges 18–75 - NCT06423885RecruitingPhase 2
Study of BL-M07D1 combination for advanced HER2-positive stomach cancer
This study tests a new combination therapy (BL-M07D1 plus another drug) for people with advanced HER2-positive stomach or gastroesophageal junction cancer. It aims to see if the combination can shrink tumors or slow cancer growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06404905RecruitingPhase 1
Testing BT02 for advanced solid tumors
This trial tests a new drug called BT02 for people with advanced solid tumors who have not had any cancer treatment before. It aims to see if BT02 is safe and how well it works.
Beijing, BiejingAges 18–75 - NCT06351527RecruitingPhase 1
Testing a new drug for B-cell lymphoma that has returned
This trial tests an experimental drug (ICP-248) alone or with another antibody therapy for people with B-cell lymphomas that have returned or not responded to treatment. It aims to see if the drug is safe and if it can shrink or control the cancer.
Plantation, FloridaAges 18 years+ - NCT07081126Recruiting
Daratumumab for late antibody-mediated rejection in kidney transplant
This trial tests whether daratumumab can help treat a type of rejection that happens more than a year after a kidney transplant. It may be an option for people who have biopsy-proven antibody-mediated rejection and new donor-specific antibodies.
MartinAges 18 years+ - NCT06112951Recruiting
ECP treatment for early signs of lung transplant rejection
This trial tests whether a therapy called extracorporeal photopheresis (ECP) can stop early, silent rejection in lung transplant patients. It is for people who have developed donor-specific antibodies but still have normal lung function.
ViennaAges 18 years+ - NCT06479291Recruiting
HCQ plus TPO-RA for ANA positive ITP
This trial tests if combining two medicines (HCQ and a TPO-RA) can help people with a type of low platelet count called ITP who also have a positive ANA blood test. The goal is to see if this combination works better than standard treatments.
Shanghai, Shanghai MunicipalityAges 15–99 - NCT04064359RecruitingPhase 1
Safety study of OBT076 for certain CD205+ solid tumors
This Phase 1 trial tests the safety of a new drug called OBT076 and looks for early signs it can help people with certain advanced (recurrent or metastatic) solid tumors that have a specific marker called CD205. You may be eligible if standard treatments are not available or no longer work, and your cancer meets lab and scan requirements.
Phoenix, ArizonaAges 18 years+ - NCT07033663Recruiting
Monoclonal antibody exposure during pregnancy and baby's immune system
This study looks at how monoclonal antibody treatments given during pregnancy affect a baby's immune system development. It compares babies whose mothers received these treatments throughout pregnancy, only in early pregnancy, or not at all.
Esplugues de Llobregat, BarcelonaAges Any age - NCT07615192Recruiting
RSV Vaccination Experiences in Queensland Infants
This study asks parents in Queensland about their infant's RSV (respiratory syncytial virus) vaccination status and experiences. RSV is a common virus that can cause serious breathing problems in babies, and this research helps understand vaccination patterns.
Brisbane, QueenslandAges 18 years+ - NCT07584954RecruitingPhase 1
Testing a new cancer immunotherapy in advanced solid tumors
This Phase 1 trial tests a new drug called IUAb190708 designed to help your immune system fight advanced or recurrent solid cancers. The study will evaluate its safety, how your body handles it, and whether it works against your tumor.
Fuzhou, FujianAges 18–75 - NCT07392372RecruitingPhase 1
Testing the safety of BNT351 in people with and without HIV
This trial tests a new antibody called BNT351 to see if it is safe and how it affects the immune system. It is for adults who either do not have HIV, or have HIV and are not currently on HIV medications.
Chicago, IllinoisAges 18–65 - NCT07595458RecruitingPhase 1
Safety Study of JST-018 Immune Treatment in Healthy Adults
This is a first-in-human safety study testing a new experimental immune therapy called JST-018. Researchers want to see how safe it is, how well your body tolerates it, and how your body processes it when given as an injection.
Las Vegas, NevadaAges 18–55 - NCT06287944RecruitingPhase 1
Targeted radiation and chemo before donor stem cell transplant
This trial tests a new approach: giving a targeted radioactive antibody (attached to a drug that finds CD38 on cancer cells) along with low-dose chemotherapy and targeted radiation to the bone marrow before a donor stem cell transplant. The goal is to prepare the body for the transplant while killing remaining cancer cells more precisely.
Duarte, CaliforniaAges 18–70 - NCT07258511RecruitingPhase 3
Comparing a new drug to Teclistamab for advanced multiple myeloma
This study tests a new experimental drug (JNJ-79635322) compared to another targeted immunotherapy (Teclistamab) for people with multiple myeloma that has returned or not responded after several prior treatments.
Phoenix, ArizonaAges 18 years+
Hear when a new Antibody trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for antibody?
- Yes. Clin2 currently lists 540 recruiting antibody studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a antibody trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a antibody trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.